
David T. Rubin
University of Chicago Division of the Biological Sciences
David T. Rubin is the Joseph B. Kirsner Professor of Medicine and a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics, an associate investigator at the University of Chicago Comprehensive Cancer Center and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. He is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, Dr. Rubin served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.
Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD which is now in its 3rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.
Appearances
- DateMay 7, 2023There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Presenter
University of Chicago Division of the Biological Sciences - DateMay 7, 2023There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Presenters
University of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 7, 2023SOCIETY: DDW
Moderators
University of Chicago Division of the Biological SciencesMayo Clinic Rochester - DateMay 9, 2023BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
- DateMay 8, 2023BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…
Presenter
Speakers
University of ChicagoUniversity of Chicago Division of the Biological Sciences - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center - DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Brigham and Women's HospitalSpeakers
Western UniversityUniversity of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 18, 2024
Presenter
University of Chicago Division of the Biological Sciences - DateMay 18, 2024
Presenters
University of California san franciscoUniversity of North Carolina School of MedicineUniversity of Chicago Division of the Biological Sciences - DateMay 19, 2024
Presenter
University of Chicago Division of the Biological Sciences - DateMay 19, 2024
Presenters
University of Chicago Division of the Biological SciencesBIDMCIcahn School of Medicine Mount Sinai HospitalCleveland Clinic - DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
Brigham and Women's HospitalWestern UniversityUniversity of Pennsylvania - DateMay 19, 2024SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
Moderators
University of California san franciscoUniversity of Chicago Division of the Biological Sciences - DateMay 18, 2024Intestinal ultrasound (IUS) is a non-invasive, repeatable, and accurate disease monitoring modality that can provide real-time assessment of inflammatory bowel disease (IBD)…
Presenter
Speakers
University of Chicago Division of the Biological Sciences - DateMay 21, 2024OBJECTIVE:The rapid emergence of IBD in newly industrialized regions supports the importance of environmental risk factors in disease etiology…
Presenter
Speakers
All India Institute of Medical SciencesUniversity of ManitobaCedars-Sinai Medical CenterUniversity of Chicago Division of the Biological SciencesTel Aviv Sourasky Medical Center - DateMay 18, 2024
Speaker
University of Chicago Division of the Biological Sciences - DateMay 18, 2024
Speakers
University of North Carolina School of MedicineUniversity of Chicago Division of the Biological Sciences - DateMay 18, 2024CARING FOR CHILDREN AND YOUNG ADULTS WITH AUTOIMMUNE LIVER DISEASE AND IBD
Moderators
Mayo Foundation for Medical Education and ResearchMayo Clinic RochesterSpeakers
University of Chicago Division of the Biological Sciences